Plasmalogen lipid deficiency is associated with several neurological conditions, most notably Alzheimer’s disease and related dementias. MLD has developed and patented novel first-in-class synthetic plasmalogen precursors that restore plasmalogen levels within the body as a novel treatment modality for these indications.

ALZHEIMER’S DISEASE

Plasmalogen deficiency has been associated with Alzheimer’s disease for over a decade and is thought to be an underlying contributing factor to disease pathogenesis. MLD’s synthetic plasmalogen therapy presents a novel approach to treating and possibly preventing dementia. Learn more here.

PARKINSON’S DISEASE

Parkinson’s disease has also been associated with plasmalogen deficiency, and results in compromised dopaminergic activity. MLD’s synthetic plasmalogen treatment has been shown to prevent the onset of Levodapa-induced dyskinesia in several primate models. Learn more here.

MULTIPLE SCLEROSIS

Myelin, the lipid sheath that protects neuronal axons and is required for optimal nerve conduction, contains plasmalogen lipids as an integral part of its structure. Augmentation of plasmalogens with MLD’s multiple sclerosis optimized synthetic plasmalogen treatment had been shown to protect against demyelination. Learn more here.